The basic research revealed that RT may increase programmed death ligand 1 (PD-L1) levels in tumor and immune cells, contributing to immunosuppression and in part explaining the clinical success of the combination of RT with programmed cell death protein 1 (PD-1)/PD-L1 immunotherapy (216). The gene discussed is PDCD1; the disease is neoplasm.